GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

1

GLP-1 receptor agonists may reduce psoriasis severity in patients with metabolic comorbidities, but evidence is limited and inconsistent.
2

Small trials indicated 40% to 80% reductions in PASI scores, especially in patients with obesity or type 2 diabetes.
3

Liraglutide and semaglutide showed significant PASI score reductions in open-label trials, but findings varied across studies.
4

GLP-1 RAs can be coadministered with other psoriasis treatments and primarily cause gastrointestinal adverse effects.
5

Current evidence is limited by small sample sizes and short follow-up, with GLP-1 RAs not approved for psoriasis treatment.

1